Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Expansion raises $80 million to drug RNA

by Ryan Cross
October 1, 2021 | A version of this story appeared in Volume 99, Issue 36

 

Expansion Therapeutics has raised $80 million in series B financing to develop small-molecule drugs that target RNA. The start-up is based on the work of its founder, Scripps Research chemist Matthew Disney, who discovered compounds targeting repetitive sequences of RNA that cause myotonic dystrophy type 1, a genetic muscle disease. Expansion Therapeutics is now developing drugs for that condition and multiple neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, and several tauopathies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.